Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Pyxis Oncology (PYXS) Equity Ratio (2020 - 2025)

Pyxis Oncology (PYXS) has 6 years of Equity Ratio data on record, last reported at 0.58 in Q4 2025.

  • On a quarterly basis, Equity Ratio fell 24.04% to 0.58 in Q4 2025 year-over-year; TTM through Dec 2025 was 0.58, a 24.04% decrease, with the full-year FY2025 number at 0.58, down 24.04% from a year prior.
  • Equity Ratio reached 0.58 in Q4 2025 per PYXS's latest filing, down from 0.65 in the prior quarter.
  • Over the last five years, Equity Ratio for PYXS hit a ceiling of 0.93 in Q4 2021 and a floor of 0.51 in Q3 2021.
  • A 5-year average of 0.71 and a median of 0.78 in 2024 define the central range for Equity Ratio.
  • Peak YoY movement for Equity Ratio: soared 264.6% in 2022, then dropped 24.04% in 2025.
  • Tracing PYXS's Equity Ratio over 5 years: stood at 0.93 in 2021, then fell by 18.47% to 0.76 in 2022, then dropped by 4.9% to 0.72 in 2023, then grew by 6.17% to 0.77 in 2024, then decreased by 24.04% to 0.58 in 2025.
  • Business Quant data shows Equity Ratio for PYXS at 0.58 in Q4 2025, 0.65 in Q3 2025, and 0.71 in Q2 2025.